Mr. Pauls has served as President, Chief Executive Officer, and director since 2010 and was Chairman of the board from 2008 to 2014. Mr. Pauls was previously the co-founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund. Prior to CentreStone, he was with Centara Corporation, another early stage venture capital fund. Before this, Mr. Pauls specialized in asset-backed securitization and structured finance at the General Motors Acceptance Corporation in Minnesota. He received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.
Dr. Verdoorn has more than 26 years of experience working with both public and private pharmaceutical and biotechnology companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb's stroke group and as the former Chief Scientific Officer for several private life sciences companies. Dr. Verdoorn earned his PhD in Neurobiology from the University of North Carolina, conducting his post-doctoral research at the Max Planck Institute with Nobel Laureate Dr. Bert Sakmann, served as Associate Professor of Pharmacology at Vanderbilt University School of Medicine and is the author of numerous publications and patents. Dr. Verdoorn was formerly Vice President of Neuroscience with DiaMedica.
Mr. Papi has extensive experience as an entrepreneurial senior executive with 38 years of demonstrated success in life sciences, investment banking, general management, product and business development, and sales and marketing leadership. Mr. Papi spent 28 years as an executive for Mylan Laboratories, providing the basis of his life science experience. His work at Mylan, as well as experience with young life science companies, provides him a unique perspective in understanding the rigors of getting through the FDA and balancing the cash flow requirements for funding the clinical process. Mr. Papi previously held a Series 7, Series 63 license and specialized in institutional equity raises, corporate development, and mergers and acquisitions. He has been a moderator at life science conferences for fund raising and has a superior track record helping young companies with strategy, financing, outreach, business expansion, networking, and communication skills.
Mr. Gurvey is a Chartered Professional Accountant (CPA, CMA) and holds a B.Sc. with an emphasis in biochemistry. Prior to joining DiaMedica, Mr. Gurvey has held Chief Financial Officer positions with both public and private companies. Mr. Gurvey began his career with Ernst & Young Chartered Accountants. Subsequently, he turned his attention to entrepreneurial endeavors and founded or co-founded several businesses including food product manufacturing, construction and home building and oil and gas. He also spent time as a Business Development representative for a division of Westcoast Energy involved with energy management.